Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

March 2, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Triple Negative Breast CancerNeoadjuvant ChemotherapyPembrolizumabTumor Microenvironment

Interventions

GENETIC

Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)

Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation

Trial Locations (1)

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors

lead

Samsung Medical Center

OTHER